Literature DB >> 12755493

Genetic and cytogenetic analyses of breast cancer yield different perspectives of a complex disease.

Peter O'Connell1.   

Abstract

Genomic instability in breast cancer results in low-level changes in DNA copy number, a significant but poorly understood mechanism underlying the genetic heterogeneity of this disorder. Two different approaches, loss of heterozygosity (LOH) and comparative genomic hybridization (CGH), have been used to probe the genetics of breast cancer evolution. LOH is a locus specific method that detects the variation in the parental origin of DNA, but is not quantitative. CGH provides a genome-wide accounting of the magnitude of DNA copy number changes, but not parental origin. Both methods have identified complex and heterogeneous patterns of DNA losses, duplications, and amplifications during breast cancer evolution. LOH and CGH technologies interrogate very distinct mechanisms driving breast tumor evolution, yet are seldom used in parallel to profile specimens. Thus, the relative significance of genetic versus numerical variations of DNA in breast cancer evolution remains undefined. This review will attempt to summarize some of the successes of these investigations, highlight some complex and confounding observations emerging from these studies, and discuss the potential of these studies to improve our understanding of breast cancer biology and treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12755493     DOI: 10.1023/a:1023037925950

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

Review 1.  Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis.

Authors:  Kenna R Mills Shaw; Carolyn N Wrobel; Joan S Brugge
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-10       Impact factor: 2.673

2.  DNA methylation changes in a human cell model of breast cancer progression.

Authors:  Sandra V Fernandez; Kara E Snider; Yue-Zhong Wu; Irma H Russo; Christoph Plass; Jose Russo
Journal:  Mutat Res       Date:  2010-03-01       Impact factor: 2.433

Review 3.  Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation?

Authors:  Alan K Meeker; Pedram Argani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-07       Impact factor: 2.673

4.  Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2.

Authors:  Sandra Louzada; Filomena Adega; Raquel Chaves
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

5.  Heterogeneity of mammary lesions represent molecular differences.

Authors:  Ruria Namba; Jeannie E Maglione; Ryan R Davis; Colin A Baron; Stephenie Liu; Condie E Carmack; Lawrence J T Young; Alexander D Borowsky; Robert D Cardiff; Jeffrey P Gregg
Journal:  BMC Cancer       Date:  2006-12-05       Impact factor: 4.430

6.  Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  J-Y Pierga; J S Reis-Filho; S J Cleator; T Dexter; A Mackay; P Simpson; K Fenwick; M Iravani; J Salter; M Hills; C Jones; A Ashworth; I E Smith; T Powles; M Dowsett
Journal:  Br J Cancer       Date:  2006-11-28       Impact factor: 7.640

7.  Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.

Authors:  Heidi Schwarzenbach; Klaus Pantel; Birthe Kemper; Cord Beeger; Friedrich Otterbach; Rainer Kimmig; Sabine Kasimir-Bauer
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

8.  A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.

Authors:  Heidi Schwarzenbach; Volkmar Müller; Cord Beeger; Miriam Gottberg; Nicole Stahmann; Klaus Pantel
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.